Phage Therapy: Past; Present and Future
Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2017 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (392 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993543536504498 |
---|---|
ctrlnum |
(CKB)4100000002484673 (oapen)https://directory.doabooks.org/handle/20.500.12854/56127 (EXLCZ)994100000002484673 |
collection |
bib_alma |
record_format |
marc |
spelling |
Abedon, Stephen T. auth Phage Therapy: Past; Present and Future Phage Therapy Frontiers Media SA 2017 1 electronic resource (392 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic. English lysins bacteriophage therapy bacterial infection treatment biofilms immunology biocontrol regulatory issues 2-88945-251-4 Garcia, Pilar auth Aminov, Rustam auth Mullany, Peter, 1959- auth |
language |
English |
format |
eBook |
author |
Abedon, Stephen T. |
spellingShingle |
Abedon, Stephen T. Phage Therapy: Past; Present and Future Frontiers Research Topics |
author_facet |
Abedon, Stephen T. Garcia, Pilar Aminov, Rustam Mullany, Peter, 1959- |
author_variant |
s t a st sta |
author2 |
Garcia, Pilar Aminov, Rustam Mullany, Peter, 1959- |
author2_variant |
p g pg r a ra p m pm |
author_sort |
Abedon, Stephen T. |
title |
Phage Therapy: Past; Present and Future |
title_full |
Phage Therapy: Past; Present and Future |
title_fullStr |
Phage Therapy: Past; Present and Future |
title_full_unstemmed |
Phage Therapy: Past; Present and Future |
title_auth |
Phage Therapy: Past; Present and Future |
title_alt |
Phage Therapy |
title_new |
Phage Therapy: Past; Present and Future |
title_sort |
phage therapy: past; present and future |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2017 |
physical |
1 electronic resource (392 p.) |
isbn |
2-88945-251-4 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT abedonstephent phagetherapypastpresentandfuture AT garciapilar phagetherapypastpresentandfuture AT aminovrustam phagetherapypastpresentandfuture AT mullanypeter phagetherapypastpresentandfuture AT abedonstephent phagetherapy AT garciapilar phagetherapy AT aminovrustam phagetherapy AT mullanypeter phagetherapy |
status_str |
n |
ids_txt_mv |
(CKB)4100000002484673 (oapen)https://directory.doabooks.org/handle/20.500.12854/56127 (EXLCZ)994100000002484673 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Phage Therapy: Past; Present and Future |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796648819973160960 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03865nam-a2200397z--4500</leader><controlfield tag="001">993543536504498</controlfield><controlfield tag="005">20240123004437.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000002484673</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/56127</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000002484673</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Abedon, Stephen T.</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phage Therapy: Past; Present and Future</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Phage Therapy</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (392 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lysins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial infection treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biofilms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biocontrol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory issues</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-251-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garcia, Pilar</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aminov, Rustam</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mullany, Peter,</subfield><subfield code="d">1959-</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-01-24 00:10:24 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2018-03-10 17:16:05 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337393530004498&Force_direct=true</subfield><subfield code="Z">5337393530004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337393530004498</subfield></datafield></record></collection> |